Description: MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. Sonelokimab optimally inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. The Company’s focus is on inflammatory diseases with a major unmet need with lead indications currently progressing into Phase 2 trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis or radiographic axial spondyloarthritis. MoonLake is headquartered in Zug, Switzerland.
Home Page: www.moonlaketx.com
MLTX Technical Analysis
Dorfstrasse 29
Zug,
6300
Switzerland
Phone:
41 415108022
Officers
| Name | Title |
|---|---|
| Dr. Jorge Santos da Silva | Co-Founder, CEO & Director |
| Dr. Kristian Reich | Co-Founder & Chief Scientific Officer |
| Mr. Matthias Bodenstedt | Chief Financial Officer |
| Mr. Oliver Daltrop Ph.D. | Chief Operations Officer |
| Ms. Carla Bretes | Director Investor Relations & Business Development |
| Mr. Nicolas Mosimann | General Counsel |
| Joana Cortez | Sr. Director Legal & Compliance |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing |
| Luciana Marques | Director of HR, People & Culture |
| Ms. Nuala Brennan | Chief Clinical Development Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.9459 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-10-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 50 |